- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Molly Burich: Industry Challenges with Biosimilars
Molly Burich, MS, associate director of public policy: biosimilars, pipeline, and reimbursement at Boehringer Ingelheim, discusses the challenges the industry faces with respect biosimilars.
Transcript:
As biosimilars become more prevalent in the United States, what is the biggest challenge that the pharmaceutical industry will face?
So, I think the biggest challenge that manufacturers face is really educating stakeholders to make sure that they understand the value of biosimilars. Physicians need to understand how they’re made, how they’re developed, and how they’re approved, as well as feel comfortable utilizing them in their patients. Patients need to see the benefit both clinically, as well as economically—the whole premise of biosimilars is around being able to bring lower-cost alternatives to market. Lastly, health plans, they need to see the benefit of pushing biosimilar use as well. All of this comes through both a combination of education and experience, and with any brand-new market, we have our work cut out for us. So, I would say the biggest challenge really revolves around ensuring a positive experience for all of our stakeholders and driving education to make sure that they’re utilized.
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
IGBA 2023: Dr Monique Mansoura Highlights the Intersection of Geopolitical Issues, Biopharma
February 19th 2023COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
